ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,116.17
0.32%
US Tech 100
17,315.60
0.44%
다우존스 지수
38,386.09
0.38%
Bitcoin
64,560.95
1.14%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Kura Oncology Inc (KURA)

  7. Kura Oncology Inc (KURA) 뉴스

KURA Kura Oncology Inc

20.06
0.41 (2.09%)
30 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Kura Oncology Inc KURA 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.41 2.09% 20.06 07:23:22
개장가 저가 고가 종가 전일 종가
19.80 19.715 20.34 20.06 19.65
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/04/202420:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
22/04/202420:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
10/04/202420:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
05/04/202420:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
06/03/202421:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
02/03/202407:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
28/02/202406:52EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/02/202406:03EDGAR2Form 8-K - Current report
28/02/202406:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
26/02/202421:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
22/02/202421:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
20/02/202421:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
16/02/202406:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/02/202414:15EDGAR2Form EFFECT - Notice of Effectiveness
15/02/202407:58EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202407:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/02/202407:21EDGAR2Form S-3 - Registration statement under Securities Act of..
02/02/202421:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
01/02/202407:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/02/202407:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/02/202407:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/01/202406:10EDGAR2Form 144 - Report of proposed sale of securities
30/01/202421:08EDGAR2Form 8-K - Current report
30/01/202421:00GLOBEKura Oncology Reports Positive Preliminary Ziftomenib..
27/01/202407:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/01/202406:08EDGAR2Form 8-K - Current report
25/01/202406:12EDGAR2Form 144 - Report of proposed sale of securities
24/01/202421:00GLOBEKura Oncology Announces Oversubscribed $150 Million Private..
05/01/202406:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/01/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/01/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/01/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/01/202406:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/01/202406:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:01EDGAR2Form 8-K - Current report
12/12/202306:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202321:30GLOBEKura Oncology’s Menin Inhibitor Ziftomenib Selected for The..
28/11/202321:30GLOBEKura Oncology to Participate in the JMP Securities..
03/11/202305:39EDGAR2Form S-3ASR - Automatic shelf registration statement of..
03/11/202305:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202305:03EDGAR2Form 8-K - Current report
03/11/202305:01GLOBEKura Oncology Reports Third Quarter 2023 Financial Results
02/11/202320:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
30/10/202320:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
27/10/202305:05GLOBEKura Oncology to Report Third Quarter 2023 Financial Results
19/10/202320:30GLOBEKura Oncology Announces First Patient Dosed in FIT-001 Trial..
18/10/202305:05GLOBEKura Oncology Announces Positive Results from..
04/10/202320:30GLOBEKura Oncology Announces Three Presentations at..
28/09/202320:30GLOBEKura Oncology Reports Preclinical Data Showing Ability of..
19/09/202320:30GLOBEKura Oncology to Participate in Cantor Global Healthcare..

최근 히스토리

NASDAQ
KURA
Kura Oncology
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유